It Takes a Few: Persistent maintenance of long-term potentiation (LTP) of glutamatergic synapses and long-term memory requires neuronal nuclear signaling that leads to gene transcription. It is unclear whether signaling produced at a single dendritic spine can be transmitted into the nucleus to regulate gene transcription. Using two-photon glutamate uncaging in combination with two-photon fluorescence lifetime imaging,
Zhai
et al. (p. 1107 ) show that induction of LTP in only three to seven dendritic spines in a hippocampal pyramidal neuron can trigger activation of nuclear extracellular signal–regulated kinase and downstream transcription factors cyclic adenosine monophosphate response element–binding protein and E26-like transcription factor-1. Thus, signaling initiated in each dendritic spine can be transmitted into the nucleus to regulate gene transcription. Furthermore, biochemical signaling in multiple dendritic branches was integrated to activate the nuclear signaling.
Experience-driven plasticity of glutamatergic synapses on striatal spiny projection neurons (SPNs) is thought to be essential to goal-directed behavior and habit formation. One major form of striatal plasticity, long-term depression (LTD), has long appeared to be expressed only pre-synaptically. Contrary to this view, nitric oxide (NO) generated by striatal interneurons was found to induce a post-synaptically expressed form of LTD at SPN glutamatergic synapses. This form of LTD was dependent on signaling through guanylyl cyclase and protein kinase G, both of which are abundantly expressed by SPNs. NO-LTD was unaffected by local synaptic activity or antagonism of endocannabinoid (eCb) and dopamine receptors, all of which modulate canonical, pre-synaptic LTD. Moreover, NO signaling disrupted induction of this canonical LTD by inhibiting dendritic Ca(2+) channels regulating eCb synthesis. These results establish an interneuron-dependent, heterosynaptic form of post-synaptic LTD that could act to promote stability of the striatal network during learning.
Levodopa-induced dyskinesia (LID) poses a significant health care challenge for Parkinson’s disease (PD) patients. Amantadine is currently the only drug proven to alleviate LID. Although its efficacy in treating LID is widely assumed to be mediated by blockade of N-methyl-D-aspartate (NMDA) glutamate receptors, our experiments demonstrate that at therapeutically relevant concentrations, amantadine preferentially blocks inward-rectifying K+ channel type 2 (Kir2) channels in striatal spiny projection neurons (SPNs) — not NMDA receptors. In so doing, amantadine enhances dendritic integration of excitatory synaptic potentials in SPNs and enhances — not antagonizes — the induction of long-term potentiation (LTP) at excitatory, axospinous synapses. Taken together, our studies suggest that the alleviation of LID in PD patients is mediated by diminishing the disparity in the excitability of direct- and indirect-pathway SPNs in the on state, rather than by disrupting LTP induction. This insight points to a pharmacological approach that could be used to effectively ameliorate LID and improve the quality of life for PD patients.